Bone and soft tissue responses to a hydrogel with piezoelectric potential in conservative non-surgical peri-implantitis treatment
Active Grant Awarded
- Award ID
- R41DE035030
- Recipient
-
Oralbiolife Inc. UEI TAFMBDJPRX49
- Awarding agency
-
National Institute of Dental and Craniofacial Research
National Institutes of Health, Department of Health and Human Services
- Obligated
- $318,017
Award facts
- Assistance listing
- 93.121 Oral Diseases and Disorders Research
- Completion date 21% complete
- Place of performance
- Southampton, PA, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute of Dental and Craniofacial Research awarded Oralbiolife Inc. $318,017 on September 9, 2026, under Assistance Listing 93.121, Oral Diseases and Disorders Research, through Grant R41DE035030. The grant funds research on bone and soft tissue responses to a hydrogel with piezoelectric potential in conservative, non-surgical treatment of peri-implantitis, an inflammatory condition that causes progressive loss of supporting bone around dental implants. The project centers on Ambrilux Dental Gel (PiezoGel), a minimally invasive hydrogel embedded with piezoelectric fillers that the company developed. The period of performance runs from September 9, 2026 through the ultimate completion date of August 31, 2027, with work performed in Southampton, Pennsylvania. The program supports basic, translational, and clinical research in dental, oral, and craniofacial health through grants and cooperative agreements, including small business research.
Description
- Abstract
- Dental implants are a well-established rehabilitation treatment with a >95% success rate at 10 years and follow-up. However, loss or failure of dental implants is still a critical problem in clinical practice. Peri- implantitis (PI) is one of the main causes of dental implant failure and is the most serious complication encountered in implant dentistry. PI is a pathological condition occurring in tissues around dental implants, characterized by inflammation in the peri-implant connective tissue and progressive loss of supporting bone. Prevalence of PI ranges from 3.6% to 22.1% at the implant level and 4.7% to 45% at the patient level. The initial approaches to PI management are through non-surgical therapy (mechanical debridement and hygiene instructions). Moderate to severe PI needs advanced surgical approaches like open flap debridement, apically positioned flap, bone grafts, guided bone regeneration, membranes, growth factors, and/or soft tissue grafts. In severe cases of osseointegration failure (severe bone loss, i.e., >50% of height), implant removal may be the only solution. The overall cost for treatment of PI ranges from $8K-$10K, excluding the initial expenses of tooth extraction and implantation ($5K-$7K). Available data trends from randomized controlled trials have indicated guided bone regeneration or the application of a bone substitute (nanocrystalline hydroxyapatite) to be an effective treatment for PI. Oral biolife has developed ambrilux dental GEL (i.e. piezogel), a minimally invasive hydrogel embedded with piezoelectric fillers that harness the benefits of hydrogels (photo curability, conformance to pocket spaces, biocompatibility) with the bioactive effects of piezoelectric stimulation. Piezoelectric materials produce electrical charges in response to external vibrations and mechanical stimulation, which induces signaling pathways for effective bone regeneration. Previous studies conducted on PG have shown robust bone regenerative effects in a periodontitis (PD) mouse model. Oral biolife has filed two patent cooperation treaty applications (US 2022/0160464 A1, WO 2020/198468 A1) in 2020, on the features of PG with the title "smart composite with antibiofilm, mineralizing and anti- infection therapeutic effects." the US patent was granted on march 25, 2025, and OBL is prosecuting the EU patent. In the current NIH sttr proposal, oral biolife aims to assess the therapeutic effect of PG in an in vivo (CANINE) model of PI. PG is expected to reduce bone destruction and enhance bone healing of dental implants due to its bone regeneration effect, which will be evaluated through radiographic and histological analysis of the soft and hard peri-implant tissue. Aim 1 will compare the radiographic bone loss and bone regeneration in PG-treated VS. Control implants in a ligature-induced PI model (beagle dogs). Aim 2 will investigate the histological changes in the peri-implant hard and soft tissues along with the analysis of bone formation, resorption, and critical inflammatory markers to decipher the mechanism of action of PG in the PI condition. The successful completion of phase I project will lay the foundation for further optimization of PG, followed by pivotal IND-enabling safety/toxicology, pharmacokinetics, and pharmacodynamic studies in phase II as well as the preparation for clinical validation.
Quick answers
Who received award R41DE035030?
R41DE035030 was awarded to Oralbiolife Inc. by National Institute of Dental and Craniofacial Research (National Institutes of Health) on September 9, 2026.
How much is award R41DE035030 worth?
$318,017 has been obligated on R41DE035030.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award